NRIX Quote, Financials, Valuation and Earnings

GT Biopharma, Inc. has a net margin of -1094.77% compared to Nurix Therapeutics, Inc.'s net margin of --. Nurix Therapeutics, Inc.'s return on equity of -55.52% beat GT Biopharma, Inc.'s return on equity of -626.24%.

Nurix Therapeutics, Inc. has a consensus price target of $28.41, signalling upside risk potential of 49.38%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 882.92%. Given that GT Biopharma, Inc. has higher upside potential than Nurix Therapeutics, Inc., analysts believe GT Biopharma, Inc. is more attractive than Nurix Therapeutics, Inc..

Nurix Therapeutics, Inc. has a beta of 1.874, which suggesting that the stock is 87.383% more volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.367%.

Nurix Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nurix Therapeutics, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.

Nurix Therapeutics, Inc. quarterly revenues are $7.9M, which are larger than GT Biopharma, Inc. quarterly revenues of --. Nurix Therapeutics, Inc.'s net income of -$86.4M is lower than GT Biopharma, Inc.'s net income of -$3.1M. Notably, Nurix Therapeutics, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nurix Therapeutics, Inc. is 18.75x versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Incyte Corp. has a net margin of -1094.77% compared to Nurix Therapeutics, Inc.'s net margin of 31.05%. Nurix Therapeutics, Inc.'s return on equity of -55.52% beat Incyte Corp.'s return on equity of 31.1%.

Nurix Therapeutics, Inc. has a consensus price target of $28.41, signalling upside risk potential of 49.38%. On the other hand Incyte Corp. has an analysts' consensus of $100.10 which suggests that it could grow by 1.2%. Given that Nurix Therapeutics, Inc. has higher upside potential than Incyte Corp., analysts believe Nurix Therapeutics, Inc. is more attractive than Incyte Corp..

Nurix Therapeutics, Inc. has a beta of 1.874, which suggesting that the stock is 87.383% more volatile than S&P 500. In comparison Incyte Corp. has a beta of 0.810, suggesting its less volatile than the S&P 500 by 18.956%.

Nurix Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Incyte Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nurix Therapeutics, Inc. pays -- of its earnings as a dividend. Incyte Corp. pays out -- of its earnings as a dividend.

Nurix Therapeutics, Inc. quarterly revenues are $7.9M, which are smaller than Incyte Corp. quarterly revenues of $1.4B. Nurix Therapeutics, Inc.'s net income of -$86.4M is lower than Incyte Corp.'s net income of $424.2M. Notably, Nurix Therapeutics, Inc.'s price-to-earnings ratio is -- while Incyte Corp.'s PE ratio is 16.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nurix Therapeutics, Inc. is 18.75x versus 4.09x for Incyte Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -1094.77% compared to Nurix Therapeutics, Inc.'s net margin of 21.32%. Nurix Therapeutics, Inc.'s return on equity of -55.52% beat Pfizer Inc.'s return on equity of 10.84%.

Nurix Therapeutics, Inc. has a consensus price target of $28.41, signalling upside risk potential of 49.38%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.54%. Given that Nurix Therapeutics, Inc. has higher upside potential than Pfizer Inc., analysts believe Nurix Therapeutics, Inc. is more attractive than Pfizer Inc..

Nurix Therapeutics, Inc. has a beta of 1.874, which suggesting that the stock is 87.383% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

Nurix Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.88% to investors and pays a quarterly dividend of $0.43 per share. Nurix Therapeutics, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Nurix Therapeutics, Inc. quarterly revenues are $7.9M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Nurix Therapeutics, Inc.'s net income of -$86.4M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Nurix Therapeutics, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nurix Therapeutics, Inc. is 18.75x versus 2.27x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -1094.77% compared to Nurix Therapeutics, Inc.'s net margin of 38.89%. Nurix Therapeutics, Inc.'s return on equity of -55.52% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Nurix Therapeutics, Inc. has a consensus price target of $28.41, signalling upside risk potential of 49.38%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $795.38 which suggests that it could grow by 2.77%. Given that Nurix Therapeutics, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Nurix Therapeutics, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Nurix Therapeutics, Inc. has a beta of 1.874, which suggesting that the stock is 87.383% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

Nurix Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.46% to investors and pays a quarterly dividend of $0.88 per share. Nurix Therapeutics, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Nurix Therapeutics, Inc. quarterly revenues are $7.9M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Nurix Therapeutics, Inc.'s net income of -$86.4M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Nurix Therapeutics, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.53x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nurix Therapeutics, Inc. is 18.75x versus 5.99x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.